Skip to main content

Table 2 Clinicopathological and immunohistochemical parameters in relation to RAI-3 immunoreactivity

From: Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

Variable Categorisation RAI-3 immunoreactivity
   n analysable lowb abundantb pc
Clinicopathological data:
Tumour stagea     
  pT1 46 29 17 0.134
  pT2 74 31 43  
  pT3 12 5 7  
  pT4 24 13 11  
Lymph node statusa     
  pN0 68 34 34 0.713
  pN1-3 83 44 39  
Histological grade     
  G1 16 9 7 0.572
  G2 67 36 31  
  G3 72 33 39  
Multifocality     
  unifocal tumour 130 69 61 0.086
  multifocal tumour 26 9 17  
Histological type     
  ductal 130 66 64 0.905
  lobular 11 5 6  
  other 13 6 7  
Immunohistochemistry (IHC):
Oestrogen receptor status     
  negative (IRS 0–2) 41 23 18 0.557
  positive (IRS 3–12) 89 45 44  
Progesterone receptor status     
  negative (IRS 0–2) 95 46 49 0.765
  positive (IRS 3–12) 41 21 20  
HER2 status     
  weak (0–2+) 109 51 58 0.638
  strong (3+) 25 13 12  
  1. aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
  2. bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
  3. cPearson test (two-sided), bold face representing significant data (P < 0.05)